Sexually Transmitted Diseases, Viral  >>  Pegasys (pegylated interferon α -2a)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
NCT00612755 / 2004-004948-45: Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4

Completed
4
43
Europe
Peginterferon alfa-2a + ribavirin, Pegasys
Hospital Clinico Universitario San Cecilio
HIV Infections, Hepatitis C
01/07
01/08
NCT00353418 / 2005-005506-23: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection

Completed
4
415
US
Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis C, Chronic
04/09
04/09
SAEI_IFN_1, NCT00553930 / 2007-000814-35: Low Dose Peginterferon-α 2a for Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients

Completed
4
71
Europe
Pegylated interferon alfa-2a and Ribavirin, Pegasys, Copegus, Pegylated interferon alfa 2a and Ribavirin, Pegasis (TM), Copegus (TM)
Sociedad Andaluza de Enfermedades Infecciosas
Hepatitis C, Chronic, HIV Infections
05/10
05/10
NCT00132210: Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients

Completed
4
200
Europe
pegylated interferon, Pegasys, PegIntron, Copegus, Rebetol
University Hospital, Bonn
Hepatitis C, HIV Infections
06/10
06/10

Download Options